Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selection.

ABSTRACT:

Abstract

Here, we present the case for next-generation sequencing of samples from patients with multiple myeloma (MM), not only identify high-risk markers but also mutations and deletions relating to immunomodulatory drugs (IMiD), and more importantly to guide the sequencing of immunotherapy regimens in response to intrinsic antigen escape as a means of treatment resistance and relapse. This is a single-center study of CD138+ selected (n = 134) bone marrow aspirate samples from patients with smoldering MM (n = 11) and MM (newly diagnosed, n = 38; relapsed, n = 79). Samples were sequenced using a targeted panel in a clinical diagnostics laboratory. Data were analyzed for high-risk markers, treatment-related resistance mechanisms, and precision medicine targets to guide the future tr

SUBMITTER: Sudha P 

PROVIDER: S-EPMC12804376 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature